ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2152

S100A11 Protein Is Increased in Rheumatoid Arthritis and Is Associated with Disease Activity and Inflammation

Lucie Andres Cerezo1, Barbora Šumová1, Klára Prajzlerová1, David Veigl2, Karel Pavelka1, Jiří Vencovský3 and Ladislav Senolt3, 1Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, 21st Orthopaedic Clinic, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, 3Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Disease Activity, inflammation and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Title: Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis - Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Calgizzarin (S100A11) is a member of the S100 protein family that acts in different tumors via regulating number of biologic functions. Recent data suggest its association with low grade inflammation in OA. The aim of the study was to analyze the expression of S100A11 in synovial tissue, synovial fluid and serum of patients with rheumatoid arthritis (RA) and osteoarthritis (OA) and to characterize its potential association with disease activity.

Methods: S100A11 expression was analyzed in synovial tissues from patients with RA (n=6) and OA (n=6) by immunohistochemistry. Immunofluorescence staining was used to co-localize S100A11 within RA synovial tissue (n=4). Serum and synovial fluid S100A11 levels were measured by ELISA (Biovendor) in 40 patients fulfilling the American College of Rheumatology criteria for the classification of RA and in 39 subjects with OA. Disease activity score based on 28 joints (DAS28-CRP) was used to assess disease activity. For in vitro experiments, peripheral blood mononuclear cells (PBMCs) and synovial fibroblasts (SFs) were obtained from patients with RA and OA (n=6-9). Expression and protein synthesis of S100A11 and cytokines were analyzed by RT-PCR, ELISA and Western Blot.

Results: The expression of S100A11 was significantly up-regulated in the synovial lining and sublining layers (p<0.01) and vessels (p<0.05) in patients with RA compared to OA and its expression was associated with fibroblasts, T lymphocytes and macrophages. Serum (14.13 [4.26-119.8] vs. 9.50 [4.95-30.16] ng/ml; p=0.004) and particularly synovial fluid (195.8 [20.22-974.2] vs. 28.40 [8.20-259.80] ng/ml; p<0.0001) S100A11 levels were significantly increased in patients with RA compared to OA. Moreover, the levels of S100A11 were higher in synovial fluid compared to serum in both RA and OA patients (p<0.0001). In patients with RA, synovial fluid S100A11 correlated significantly with DAS28 (r=0.350, p=0.027), CRP (r=0.463, p=0.003), synovial fluid leukocyte count (r=0.677, p<0.001), ACPA (r=0.424, p=0.006), but not with IgM-RF (r=0.059, p=0.719). No such associations were observed in serum. In addition, S100A11 is synthetized and spontaneously secreted in higher concentrations by PBMCs (p=0.01) and SFs (p=0.03) isolated from patients with RA in comparison with OA. Extracellular S100A11 protein stimulates the production of pro-inflammatory cytokines IL-6 and TNFα in PBMCs (p<0.05) and SFs (p<0.01).

Conclusion: Our data provide the first evidence of S100A11 up-regulation and its association with inflammation and disease activity in patients with RA. Acknowledgement: Supported by grant 15-34065A of the Agency for Healthcare Research of the Czech Republic and MHCR 023728.


Disclosure: L. Andres Cerezo, None; B. Šumová, None; K. Prajzlerová, None; D. Veigl, None; K. Pavelka, None; J. Vencovský, None; L. Senolt, None.

To cite this abstract in AMA style:

Andres Cerezo L, Šumová B, Prajzlerová K, Veigl D, Pavelka K, Vencovský J, Senolt L. S100A11 Protein Is Increased in Rheumatoid Arthritis and Is Associated with Disease Activity and Inflammation [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/s100a11-protein-is-increased-in-rheumatoid-arthritis-and-is-associated-with-disease-activity-and-inflammation/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/s100a11-protein-is-increased-in-rheumatoid-arthritis-and-is-associated-with-disease-activity-and-inflammation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology